Loading...
•
Mar 31, 2020
Arvinas Q1 2020 Earnings Report
Reported financial results for the first quarter ended March 31, 2020 and provided a corporate update.
Key Takeaways
Arvinas reported revenue of $6.2 million and a net loss of $21.7 million for the first quarter ended March 31, 2020. The company's cash, cash equivalents, and marketable securities were $262.8 million as of March 31, 2020, which is expected to fund operations into 2022.
Arvinas expects to share updated data from the dose escalation portion of its Phase 1/2 clinical study in men with mCRPC in a presentation at the virtual ASCO annual meeting in the second quarter of 2020 for the ARV-110 program.
For the ARV-471 program, which is being studied in patients with locally advanced or metastatic ER+/HER2- breast cancer, Arvinas expects to share data from the dose escalation portion of its Phase 1/2 clinical trial in the second half of 2020.
In the second half of 2020, Arvinas expects to provide information about the advancement of additional programs in its robust preclinical pipeline.
Cash, cash equivalents, and marketable securities were $262.8 million as of March 31, 2020.
Revenue by Segment
Forward Guidance
Based on its current operating plan, Arvinas expects its cash, cash equivalents, and marketable securities will be sufficient to fund its planned operating expenses and capital expenditures into 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...